Insider buying last 90 days
No open-market insider purchases were filed for GILD in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GILD insider filing, plotted on the chart in Gekko.Open GILD in Gekko
NASDAQ: GILD
Gilead Sciences (GILD) Stock Analysis & Forecast
Nov 4 close
$174.48+7.01 (+4.2%)
Gekko Brief
AI summaryNov 4 closeGilead shares rallied 4.19% to $174.48 this week, snapping a two-day losing streak and outperforming the broader market on a day the S&P 500 and Dow also posted gains. The move follows last week's Q3 2026 results, where base business sales rose 16% year-over-year, HIV sales grew 18% with Biktarvy at an all-time high U.S. market share, and Trodelvy surged 42%. Jefferies reiterated a Buy rating with a $196.00 price target, citing a lower expected IRA impact on Biktarvy revenue, while Gilead and Kite also outlined upcoming oncology data at ASH 2026 and HIV presentations planned for Glasgow.
Gilead trades at $174.48, above both its 50-day average of $152.29 and 200-day average of $140.59, with the 50-day above the 200-day, a supportive trend backdrop. The GekkoIndex reading sits at 41.3, placing the stock in the Distribution zone, down 9.7 points over five sessions. The price stands 12% above Gekko Fair Value of $155.75.
The next earnings date falls on 9 February 2027, 96 days out and beyond a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in the current windows, leaving smart-money signals quiet for now. Seasonality over the next 20 trading days has averaged a 3% gain across 5 years, rising in 4 of them. The stretch above Gekko Fair Value alongside the Distribution zone reading is worth noting.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Gilead Sciences price vs fair value
Close $174.48200-day averageGekko Fair Value $155.75
Gilead Sciences quick facts
- Market cap
- $216.3B
- P/E ratio
- —
- Forward P/E
- 17.3
- EPS, TTM
- −$3.13
- Revenue, TTM
- $30.99B
- Profit margin
- -12.5%
- Dividend yield
- 1.90%
- Beta
- 0.37
- Volume
- 9.51M avg 6.59M
- 1-year return
- +43.0%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±4.2%
- 50-day average
- $152.29
- 200-day average
- $140.59
- Next earnings
- Feb 9 after close
- Shares outstanding
- 1.24B
Gilead Sciences swing-trade checklist
Gilead Sciences scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $174.48 is above the 50-day ($152.29) and 200-day ($140.59) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
41.3, Distribution
Reading 41.3 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
12.0% above
Price is 12% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 96 days
Next report Feb 9, 2027, 96 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.0% on average
From this point in the calendar, the next 20 trading days averaged +3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Gilead Sciences stock chart and price history
Gilead Sciences closed at $174.48 on Nov 4, 2026, +43.0% over the past year, inside a 52-week range of $116.88 to $175.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +21.0%
- 3 months
- +33.3%
- 6 months
- +28.0%
- 1 year
- +43.0%
The full GILD chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GILD in Gekko
Follow Gilead Sciences through every session
Put GILD on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GILD in GekkoFree for 7 days. No credit card required.
About Gilead Sciences
Gilead Sciences develops and sells medicines aimed at serious illnesses, with a reach that extends across the United States, Europe, and other markets worldwide. It is widely recognized for its HIV/AIDS treatments, a lineup that includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, and related therapies. The company also supplies Veklury, an intravenous treatment developed in response to the coronavirus pandemic, alongside medicines for liver disease, cancer, blood disorders, and patients receiving cell therapy.
Beyond its own product lines, Gilead works with outside partners to move new treatments through development. Its collaborators include Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen Sciences Ireland, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck. Its portfolio also covers narrower conditions such as pulmonary arterial hypertension, chronic angina, and severe fungal infections, treated respectively with Letairis, Ranexa, and AmBisome.
The company was established in 1987 and runs its headquarters out of Foster City, California. Its shares trade on the NASDAQ under the ticker GILD.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- gilead.com
Gilead Sciences GekkoIndex: the smart money zone
Gilead Sciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 41.3, in the Distribution zone, down 9.7 points over five sessions.
41.3Distribution
Down 9.7 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 43 | −1.0% | −1.4% | ||
| Accumulation | 170 | +0.8% | +1.5% | ||
| Neutral | 439 | +0.7% | +3.2% | ||
| Distribution (current zone) | 41 | +0.4% | +0.9% | ||
| Selling | 4 | Too few readings yet | |||
Average GILD share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the GILD price, zone by zone.Track GILD in Gekko
Is Gilead Sciences stock overvalued? Gekko Fair Value
Gilead Sciences trades 12.0% above Gekko Fair Value of $155.75, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Gilead Sciences shares are worth, recalculated every trading day.
$155.75
Gekko Fair Value, Nov 4, 2026
12.0% Overvalued
At the end of Aug 2026 the price was 3.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open GILD in Gekko
Gilead Sciences insider and Congress trading
No open-market insider purchases were filed for Gilead Sciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GILD were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GILD, plotted on the chart in Gekko.Open GILD in Gekko
Buybacks
Gilead Sciences has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2026
- $370.0M
- As a share of market cap
- 0.17%
- Trailing four quarters
- $1.37B
From company filings.
Hedge funds and billionaires quarter ended Dec 31
0of the funds Gekko tracks hold GILD.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Gilead Sciences earnings: next date and track record
Gilead Sciences reports on Feb 9, 2027, after the close (96 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 9, 2027
Expected after the close, 96 days away
- EPS estimate
- $1.39
- Revenue estimate
- $8.28B
8 of 8reports beat the EPS estimate
±4.3%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Gilead reported Q3 2026 base business sales up 16% year-over-year, the strongest growth in over a decade. HIV sales grew 18% YoY with Biktarvy at all-time high U.S. market share; Yeztugo and Descovy PrEP combined hit a $4B annual run rate. Trodelvy sales surged 42% YoY reaching ~$2B annual run rate. Total product sales ex-Veklury reached $8.2B. Four potential approvals targeted for 2026 including anito-cel.
- Guidance
- Management raised 2026 base business revenue guidance by $1.6B over the course of the year. Biktarvy's CMS Maximum Fair Price determination will negatively impact revenues in 2028. Islatravir plus lenacapavir NDA filing expected in 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $2.55 est $2.19 | $8.30B est $7.81B | +7.2% |
| Aug 4, 2026 | −$6.75 est −$7.25 | $7.80B est $7.40B | +0.5% |
| May 7, 2026 | $2.03 est $1.89 | $6.96B est $6.91B | −3.6% |
| Feb 10, 2026 | $1.86 est $1.81 | $7.93B est $7.69B | +2.7% |
| Oct 30, 2025 | $2.47 est $2.13 | $7.77B est $7.45B | +1.1% |
| Aug 7, 2025 | $2.01 est $1.96 | $7.08B est $6.98B | +8.3% |
| Apr 24, 2025 | $1.81 est $1.77 | $6.67B est $6.81B | −3.0% |
| Feb 11, 2025 | $1.90 est $1.70 | $7.57B est $7.15B | +8.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Gilead Sciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Gilead Sciences is $172.50, −1.1% from the last close, from 22 firms rating the stock in the last 90 days.
$172.50consensus 12-month target, −1.1% from the last close
Now $174.48Avg $172.50
Low $131High $200
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | BMO Capital | $184 | +5.5% |
| Nov 2 | Leerink Partners | $145 | −16.9% |
| Oct 30 | Wells Fargo | $190 | +8.9% |
| Oct 30 | Needham | $200 | +14.6% |
| Oct 30 | BMO Capital | $184 | +5.5% |
+0.9%average 20-day move after past Distribution readings
+3.0%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Gilead Sciences seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Gilead Sciences averaged +3.0% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.8% | 3 of 5 |
| Next 10 trading days | +0.1% | 3 of 5 |
| Next 15 trading days | +1.5% | 4 of 5 |
| Next 20 trading days | +3.0% | 4 of 5 |
| Next 30 trading days | +3.1% | 3 of 5 |
For scale, GILD’s typical 20-trading-day move in either direction is about 4.2%.
Gilead Sciences market cap and key statistics
Gilead Sciences’s market cap is $216.3B and revenue of $30.99B over the last twelve months.
Valuation
- Market cap
- $216.3B
- Forward P/E
- 17.3
- EPS, TTM
- −$3.13
- Gekko Fair Value
- $155.75
Trading
- Volume
- 9.51M
- Avg volume, 20 days
- 6.59M
- 52-week high
- $175.65
- 52-week low
- $116.88
- Shares outstanding
- 1.24B
Financials
- Revenue, TTM
- $30.99B
- Profit margin
- -12.5%
- Return on equity
- -22.5%
- Quarterly earnings growth, YoY
- −20.2%
Risk and income
- Beta
- 0.37
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±4.2%
- Dividend yield
- 1.90%
Gilead Sciences stock news this week
Coverage of Gilead Sciences this week reads positive: 14 positive, 8 neutral and 1 negative headlines.
- Gilead Sciences Inc. stock outperforms competitors on strong trading dayMarketWatch, Nov 4
- Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026Stock Titan, Nov 4
- Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research, Nov 4
- Jefferies reiterates Buy on Gilead stock, sees lower IRA impactInvesting.com, Nov 4
- Gilead Sciences Inc. stock underperforms Tuesday when compared to competitorsMarketWatch, Nov 3
- Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV GlasgowBioSpace, Nov 3
Gilead Sciences peers
Gilead Sciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Distribution | 18.1% below |
| MRNAModerna | Neutral | 54.9% above |
| NTRANatera | Neutral | 0.8% below |
| IQVIQVIA | Neutral | 2.4% above |
| UTHRUnited Therapeutics | Distribution | 9.1% below |
| NBIXNeurocrine Biosciences | Distribution | 31.9% below |
A peer links to its own page where one exists.
Gilead Sciences stock FAQ
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $216.3B at the Nov 4, 2026 close of $174.48, with 1.24B shares outstanding.
What is the Gilead Sciences stock forecast?
The consensus analyst 12-month price target for Gilead Sciences is $172.50, −1.1% from the last close. Of the 22 firms that rated the stock in the last 90 days, 17 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Gilead Sciences stock overvalued or undervalued?
On Gekko’s estimate Gilead Sciences is overvalued: the Nov 4, 2026 close of $174.48 is 12.0% above Gekko Fair Value of $155.75. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Gilead Sciences report earnings next?
Gilead Sciences is expected to report on Feb 9, 2027, after the market closes (96 days away). Analysts expect earnings of $1.39 per share on revenue of $8.28B. Gilead Sciences beat the earnings estimate in 8 of its last 8 reports, moving 4.3% on average across the report.
What is Gilead Sciences’s 52-week high and low?
Gilead Sciences’s 52-week high is $175.65 and its 52-week low is $116.88; it closed at $174.48 on Nov 4, 2026, +43.0% over the past year.
Is Gilead Sciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Gilead Sciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.